The future of brain banking in Australia: an integrated brain and body biolibrary

Amanda Rush and Greg T Sutherland
Med J Aust 2021; 214 (10): . || doi: 10.5694/mja2.51049
Published online: 17 May 2021

A virtual brain bank could maximise the potential of brain donation by extending the core physical bank to include existing repositories of clinical tissues and data

Brain banking, whereby post mortem brains are harvested, processed, stored and made available to facilitate health and medical research, provides scientists with an unparalleled resource for macroscopic, microscopic and molecular investigations into many brain conditions. The human brain is seen as the final frontier of scientific research, with many cognitive processes and neurological diseases exclusively manifesting in humans. This uniqueness has been postulated as an explanation for why many brain disease drug leads do not progress past the acknowledged “valley of death” whereby success in animals is not translated to human clinical trials.1 For many brain researchers, human post mortem tissue is therefore preferred or essential for their investigations.

  • 1 NSW Health Statewide Biobank, Sydney, NSW
  • 2 Charles Perkins Centre, University of Sydney, Sydney, NSW



Funding to support this research was provided by the NSW Ministry of Health (PhD Program; Amanda Rush), and the Faculty of Medicine and Health, University of Sydney (Sydney Research Accelerator Fellowship; Greg Sutherland). Publication of the study results was not contingent on the sponsors’ approval or censorship of the manuscript. The contents of the published material are solely the responsibility of the individual authors and do not reflect the views of NSW Health. The authors acknowledge the staff of the NSW Brain Tissue Resource Centre and the NSW Health Statewide Biobank for their helpful discussions.

Competing interests:

No relevant disclosures.

  • 1. Hutson PH, Clark JA, Cross AJ. CNS target identification and validation: avoiding the valley of death or naive optimism? Annu Rev Pharmacol Toxicol 2017; 57: 171–187.
  • 2. Huitinga I, Webster MJ, editors. Brain banking (Vol. 150). In: Aminoff MJ, Boller F, Swaab DF, series editors. Handbook of clinical neurology. Amsterdam: Elsevier, 2018.
  • 3. Zielke HR, Mash DC. A review of brain biorepository management and operations. Handb Clin Neurol 2018; 150: 83–92.
  • 4. Sutherland GT, Sheedy D, Stevens J, et al. The NSW Brain Tissue Resource Centre: banking for alcohol and major neuropsychiatric disorders research. Alcohol 2016; 52: 33–39.
  • 5. Baumgartner A, Anthony D. The decline of the autopsy in Rhode Island and nationwide: past trends and future directions. R I Med J (2013) 2016; 99: 36–38.
  • 6. Jack CR Jr., Barrio JR, Kepe V. Cerebral amyloid PET imaging in Alzheimer’s disease. Acta Neuropathol 2013; 126: 643–657.
  • 7. Varma VR, Oommen AM, Varma S, et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study. PLoS Med 2018; 15: e1002482.
  • 8. Zetterberg H, Burnham SC. Blood‐based molecular biomarkers for Alzheimer’s disease. Mol Brain 2019; 12: 26.
  • 9. Kanton S, Boyle MJ, He Z, et al. Organoid single‐cell genomic atlas uncovers human‐specific features of brain development. Nature 2019; 574: 418–422.
  • 10. Sutherland GT, Siebert GA, Kril JJ, Mellick GD. Knowing me, knowing you: can a knowledge of risk factors for Alzheimer’s disease prove useful in understanding the pathogenesis of Parkinson’s disease? J Alzheimers Dis 2011; 25: 395–415.
  • 11. Shen L, Thompson PM, Potkin SG, et al. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav 2014; 8: 183–207.
  • 12. Shinohara M, Sato N. Bidirectional interactions between diabetes and Alzheimer’s disease. Neurochem Int 2017; 108: 296–302.
  • 13. Norton S, Matthews FE, Barnes DE, et al. Potential for primary prevention of Alzheimer’s disease: an analysis of population‐based data. Lancet Neurol 2014; 13: 788–794.
  • 14. Driver JA. Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence. Biogerontology 2014; 15: 547–557.
  • 15. Australian Government. 2016 National Research Infrastructure Roadmap. Canberra: Australian Government, 2017. (viewed Apr 2021).
  • 16. Foote C, Hockham C, Sukkar L, et al. EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): protocol for an Australian linked cohort study. JMIR Res Protoc 2020; 9: e15646.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.